Posts tagged 2022

Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position

Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered peptides and therapeutic proteins, announced today the execution of the following key milestones:

Intuitive Venture PartnersJuly 18, 20222022, entera bio

Aeluma, Inc. Names Former Head of Business Development for Continental's LiDAR Product Line, Thomas Laux, as Vice President of Business Development

Aeluma, Inc., announced today that it has named Thomas Laux as Vice President of Business Development.

Intuitive Venture PartnersMay 3, 2022aeluma, 2022